All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

P21 Peptide

P21 peptide is a synthetic compound studied for its potential influence on neuronal growth, cognitive function, and neuroprotective signaling pathways. It was developed in research exploring molecules that could affect brain plasticity and mechanisms involved in memory formation.

P21 peptide is derived from a region of Ciliary neurotrophic factor, a protein involved in neuronal survival and differentiation.

Because of its potential effects on neural signaling and synaptic development, P21 peptide has been investigated in experimental studies related to neurodegenerative diseases, cognitive decline, and brain repair mechanisms.

Despite scientific interest in the compound, P21 remains an experimental peptide and has not been approved as a pharmaceutical medication by major regulatory authorities.

How P21 peptide works

P21 peptide has been studied for its influence on neurotrophic signaling pathways, which regulate neuronal growth and survival. Experimental research suggests that the peptide may:

  • interact with signaling pathways involved in neuronal differentiation and survival

  • influence mechanisms related to synaptic plasticity and memory formation

  • support biological processes associated with neuronal repair and regeneration

  • modulate molecular pathways involved in brain-derived neurotrophic signaling

Because neurotrophic signaling plays an important role in maintaining healthy neural networks, compounds affecting these pathways are of interest in research related to cognitive function and neurodegenerative diseases.

Clinical trials and evidence

Research involving P21 peptide has primarily been conducted in laboratory studies and animal models. Experimental investigations have explored:

  • the peptide’s effects on neuronal growth and synaptic plasticity

  • experimental models of cognitive decline and neurodegenerative disease

  • mechanisms related to neurotrophic signaling and memory formation

Some studies in experimental models have suggested that P21 peptide may influence neuronal survival and cognitive performance.

However, the compound has not undergone extensive clinical trials in humans, and most available information comes from preclinical research rather than controlled clinical studies.

Possible side effects of P21 peptide:

Because P21 peptide has primarily been studied in experimental settings, its complete safety profile in humans has not been fully established. Possible or theoretical side effects may include:

  • headache

  • fatigue

  • temporary changes in cognitive perception

  • injection site reactions

Further research is required to determine the long-term safety and potential risks associated with this peptide.

P21 peptide is an experimental compound studied primarily in neuroscience and neurodegenerative disease research. It is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

P21 peptide
Action: Neurogenesis and synaptic plasticity support | Category: neurotrophic peptide
Experimental dosage: 100-350 mcg | Frequency: every day | Timing: freely | Cycle on: 10-30 days — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■▢▢▢ | Safety: ■■▢▢▢

Related peptides

Peptides from the same functional group:Cerebrolysin, Cortagen, Dihexa, DSIP, Pinealon, Selank

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged